Login to Your Account



THOMSON REUTERS RECAP 2013 BIOPHARMA DEALS

‘Desperate’ for assets, pharmas grow more creative in dealmaking

By Marie Powers
Staff Writer

Tuesday, January 21, 2014
The take-home message from Thomson Reuters Recap’s analysis of 2013 biopharma dealmaking was no surprise: It was a very good year across the board for initial public offerings (IPO), M&A and licensing agreements. However, the analysis also suggested that pharmas and biotechs are beginning to dance to a slightly different beat.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription